Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg £68
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  3. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  4. Milanovic M, et al. 2021. Cancer Res. 81:426. PubMed
  5. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  6. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  7. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  8. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  9. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  10. Chowdhury S, et al. 2022. Cancer Res. 82:2640. PubMed
  11. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  12. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  13. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  14. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  15. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  16. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  17. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  18. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  19. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  20. Wang L, et al. 2022. Nutrients. 15: . PubMed
  21. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  22. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  23. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  24. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  25. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  26. Milanovic M, et al. 2021. J Immunol. 206:1228. PubMed
  27. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  28. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  29. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  30. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  31. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  32. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  33. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  34. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  35. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  36. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  37. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  38. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  39. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  40. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  41. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  42. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  43. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
  44. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  45. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  46. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  47. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  48. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  49. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  50. Pagano G, et al. 2023. Haematologica. . PubMed
  51. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  52. Liu J, et al. 2019. Immunity. 50:600. PubMed
  53. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  54. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  55. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  56. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  57. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  58. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  59. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  60. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  61. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  62. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  63. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  64. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  65. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  66. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  67. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  68. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  69. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  70. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  71. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  72. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  73. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  74. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  75. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  76. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  77. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  78. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  79. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  80. Morales D, et al. 2015. J Virol. 89:337. PubMed
  81. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  82. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  83. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  84. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  85. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  86. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  87. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  88. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  89. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  90. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  91. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  92. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  93. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  94. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  95. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  96. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  97. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  98. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  99. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  100. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  101. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  102. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  103. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  104. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  105. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  106. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  107. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  108. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  109. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  110. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  111. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  112. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  113. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  114. Wu J, et al. 2020. Immunity. 53:115. PubMed
  115. Köchl R, et al. 2020. Elife. 9:00. PubMed
  116. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  117. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  118. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  119. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  120. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  121. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  122. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  123. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  124. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  125. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  126. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  127. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  128. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  129. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  130. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  131. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  132. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  133. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  134. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  135. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  136. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  137. Yang J, et al. 2020. Nature. 586:572. PubMed
  138. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  139. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  140. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  141. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  142. Wan X, et al. 2018. Nature. 560:107. PubMed
  143. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  144. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  145. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  146. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  147. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  148. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  149. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  150. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  151. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  152. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  153. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  154. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  155. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  156. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  157. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  158. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  159. Du J, et al. 2018. AMB Express. 8:158. PubMed
  160. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  161. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  162. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  163. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  164. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  165. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  166. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  167. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  168. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  169. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  170. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  171. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  172. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  173. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  174. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  175. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  176. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  177. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  178. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  179. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  180. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  181. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  182. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  183. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  184. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  185. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  186. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  187. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  188. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  189. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  190. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  191. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  192. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  193. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  194. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  195. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  196. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  197. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  198. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  199. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  200. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  201. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  202. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  203. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  204. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  205. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  206. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  207. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  208. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  209. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  210. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  211. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  212. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  213. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  214. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  215. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  216. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  217. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  218. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  219. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  220. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  221. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  222. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  223. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  224. Li H, et al. 2022. iScience. 25:104481. PubMed
  225. Wang X, et al. 2022. Elife. 11:. PubMed
  226. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  227. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  228. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  229. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  230. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  231. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  232. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  233. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  234. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  235. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  236. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  237. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  238. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  239. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  240. Xie L, et al. 2020. Infect Immun. :88. PubMed
  241. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  242. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  243. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  244. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  245. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  246. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  247. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  248. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  249. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  250. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  251. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  252. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312744 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account